• 1. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 2. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877

Introduction to 1-(4-Amino-2-bromopyridin-3-yl)ethanone (CAS No. 1393573-65-3)

1-(4-Amino-2-bromopyridin-3-yl)ethanone, identified by its Chemical Abstracts Service (CAS) number 1393573-65-3, is a significant compound in the realm of pharmaceutical and chemical research. This heterocyclic ketone features a pyridine core substituted with an amino group at the 4-position and a bromine atom at the 2-position, coupled with an acetyl moiety at the 3-position. Its unique structural attributes make it a valuable intermediate in the synthesis of various biologically active molecules, particularly in the development of small-molecule drugs targeting neurological and inflammatory disorders.

The 1-(4-amino-2-bromopyridin-3-yl)ethanone structure is characterized by its ability to participate in diverse chemical reactions, including nucleophilic substitution, condensation, and coupling reactions. These reactivity patterns have positioned it as a key building block in medicinal chemistry, enabling the construction of complex scaffolds with potential therapeutic applications. The presence of both electron-withdrawing and electron-donating groups on the pyridine ring enhances its versatility, allowing for fine-tuning of physicochemical properties such as solubility, permeability, and metabolic stability.

In recent years, 1-(4-amino-2-bromopyridin-3-yl)ethanone has garnered attention for its role in the synthesis of kinase inhibitors, which are pivotal in treating cancers and inflammatory diseases. For instance, derivatives of this compound have been explored as modulators of Janus kinases (JAKs), a family of enzymes implicated in autoimmune disorders like rheumatoid arthritis. The bromine substituent at the 2-position facilitates cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings, enabling the introduction of aryl or heteroaryl groups to generate more intricate molecular structures.

Moreover, the 4-amino group provides a site for further functionalization, allowing chemists to attach pharmacophores that enhance target binding affinity. This adaptability has been exploited in the design of novel antiviral agents, where 1-(4-amino-2-bromopyridin-3-yl)ethanone serves as a precursor for compounds targeting viral proteases and polymerases. The compound’s ability to undergo selective modifications has also made it useful in generating libraries for high-throughput screening (HTS), aiding in the rapid identification of lead compounds with desired biological activity.

Recent advancements in computational chemistry have further highlighted the potential of 1-(4-amino-2-bromopyridin-3-yl)ethanone as a scaffold for drug discovery. Molecular docking studies have demonstrated its binding interactions with various protein targets, including transcription factors and receptor tyrosine kinases. These virtual screening approaches have guided experimental efforts toward optimizing potency and selectivity, reducing off-target effects. The integration of machine learning algorithms has also enabled predictive modeling of pharmacokinetic properties, streamlining the development process from hit identification to candidate optimization.

The synthesis of 1-(4-amino-2-bromopyridin-3-yl)ethanone typically involves multi-step organic transformations starting from commercially available pyridine derivatives. Key steps often include halogenation at the 2-position followed by selective acylation to introduce the carbonyl group at the 3-position. Recent methodologies have focused on improving yields and minimizing byproduct formation through catalytic systems such as palladium-based catalysts or transition-metal complexes. Green chemistry principles have also been applied, emphasizing solvent-free conditions or using environmentally benign reagents to enhance sustainability.

In clinical research, derivatives of 1-(4-amino-2-bromopyridin-3-yl)ethanone have shown promise in preclinical models of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The pyridine scaffold is known to interact with biological pathways involving acetylcholinesterase inhibition and oxidative stress modulation. Preclinical studies have revealed that certain analogs exhibit neuroprotective effects by mitigating mitochondrial dysfunction and reducing neuroinflammation. These findings have spurred interest in developing novel therapeutics based on this structural motif.

The role of 1-(4-amino-2-bromopyridin-3-yl)ethanone extends beyond academia into industrial applications. Pharmaceutical companies utilize this compound as a key intermediate in large-scale syntheses required for clinical trials and commercial drug production. Continuous flow chemistry has been explored to enhance scalability while maintaining high purity standards, ensuring that pharmaceutical-grade material is produced efficiently. Such innovations underscore the compound’s importance not only as a research tool but also as a practical component in drug manufacturing processes.

Future directions in the study of 1-(4-amino-2-bromopyridin-3-yl)ethanone may involve exploring its potential in combination therapies or addressing emerging resistance mechanisms observed in existing treatments. Researchers are investigating how structural modifications can influence pharmacodynamics and pharmacokinetics, aiming to develop next-generation drugs with improved efficacy profiles. Collaborative efforts between synthetic chemists and bioinformaticians will be crucial in uncovering new applications for this versatile compound.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)